相关实验视频
Updated: Jun 28, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
合成,表征,在体DFT,分子对接,和动力学模拟研究的PhenylhydrazonoPhenoxyquinolones他们的低血糖效率的合成,表征
Narayanaswamy Lohitha1, Peruru Hemanth Kumar1, Sundaramoorthy Sarveswari1
1Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India.
ACS omega
|April 15, 2024
概括
研究人员用计算方法合成了新型的化和化衍生物,并评估了它们作为α-amylase抑制剂的潜力. 一种化合物显示出有前途的结合亲和力,表明其作为候选药物的潜力.
科学领域:
- 药用化学 医学化学
- 计算化学计算化学
- 药物发现 药物发现 药物发现
背景情况:
- 阿尔法氨基酶是治疗糖尿病的关键标.
- 需要新的抑制剂来改善治疗结果.
- 氧基诺林衍生物为药物开发提供了一个有前途的支架.
研究的目的:
- 为了合成和描述新型的基氨酸和基诺林衍生物.
- 以计算方式选这些衍生物的α-氨酶抑制活性.
- 研究潜在抑制剂的结合相互作用和稳定性.
主要方法:
- 合成和光谱学表征 (1HNMR,13CNMR,HREI-MS). 在这种情况下,
- 在研究中:药物相似性,ADMET分析,DFT计算,分子对接和分子动力学模拟.
- 对抗α-氨酶 (PDB 6OCN) 的对接.
主要成果:
- 合成了24种新型的基诺衍生物,产量很好.
- 计算研究显示了有利的反应性和类似药物的特性.
- 一种衍生品对α-amylase表现出显著的负键结合亲和力.
- 分子动力学模拟证实了稳定的结合相互作用.
结论:
- 合成的phenylhydrazono氧诺林衍生物显示出作为α-amylase抑制剂的潜力.
- 通过计算选识别的化合物需要进一步调查.
- 这项研究为开发新的抗糖尿病药物提供了基础.
相关概念视频
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oxidation of Phenols to Quinones
3.0K
In the presence of oxidizing agents, phenols are oxidized to quinones. Quinones can be easily reduced back to phenols using mild reducing agents. The electron-donating hydroxyl group enhances the reactivity of the aromatic ring, enabling oxidation of the ring even in the absence of an α hydrogen.
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
3.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
195
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195
Oral Hypoglycemic Agents: Sulfonylureas
207
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
207
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174

